New Phase I clinical trial to treat subjects with xerostomia after XRT for Head and Neck Cancer gets green light from University of Wisconsin-Madison IRB.
A new clinical trial covered under an IND held by UW Program for Advanced Cell Therapy has received regulatory approval to begin enrolling subjects. Randall Kimple MD, PhD, UW Associate Professor of Human Oncology is the Principal Investigator of the new clinical protocol titled, “A Phase I Dose Escalation Trial of Mesenchymal Stromal Cells (#mscs) in Patients with #Xerostomia after #radiationtherapy for Head and Neck Cancer”. Following a pilot safety study completed at UW Carbone Cancer Center where interferon-γ activated #MSCs were injected in a single submandibular gland (NCT04489732), in this phase I clinical trial, MSCs will be injected into both submandibular glands. This clinical trial is posted at ClinicalTrials.gov (NCT05820711). Accrual of 30 subjects at UW Health is anticipated to begin in May of 2023